Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5AZA-alt-DEC in Myeloid Malignancies
NCT04187703Phase 1Recruiting
- Start
- Nov 2020
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine and decitabine in myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN). Primary endpoint: Overall Response Rate. Started Nov 2020; status: recruiting.
02
Drugs
azacitidinedecitabine
03
Conditions
myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT04187703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187703.